# BridgeBio Oncology Therapeutics, Inc.: financial statements, quarterly

BBOT · Nasdaq · CIK 1869105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bbot.md) · [Financials](/companies/bbot/financials.md) · [Filings](/companies/bbot/filings.md) · [Insiders](/companies/bbot/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bbot/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | [17.9](/filings/0001193125-25-277834.md) | [19.5 d](/filings/0001193125-26-094112.md) | [20.6](/filings/0001193125-26-219829.md) | [27.4](/filings/0001193125-26-344661.md) | [35.1](/filings/0001193125-25-277834.md) | [38.1 d](/filings/0001193125-26-094112.md) | [39.8](/filings/0001193125-26-219829.md) | [49.2](/filings/0001193125-26-344661.md) |
| Operating income | $m | [(0.1)](/filings/0001213900-25-044424.md) | [(0.2)](/filings/0001213900-25-070659.md) | [(19.7)](/filings/0001193125-25-277834.md) | [(21.9) d](/filings/0001193125-26-094112.md) | [(23.1)](/filings/0001193125-26-219829.md) | [(30.1)](/filings/0001193125-26-344661.md) | [(49.2)](/filings/0001193125-25-277834.md) | [(43.4) d](/filings/0001193125-26-094112.md) | [(46.2)](/filings/0001193125-26-219829.md) | [(60.2)](/filings/0001193125-26-344661.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001193125-25-277834.md) | [0.0 d](/filings/0001193125-26-094112.md) | [0.0](/filings/0001213900-25-044424.md) | [0.0](/filings/0001193125-26-344661.md) | [0.0](/filings/0001193125-25-277834.md) | [0.0 d](/filings/0001193125-26-094112.md) | not reported | [0.0](/filings/0001193125-26-344661.md) |
| Net income | $m | [(15.4)](/filings/0001193125-25-277834.md) | [(21.8)](/filings/0001193125-25-277834.md) | [(17.3)](/filings/0001193125-25-277834.md) | [(19.7) d](/filings/0001193125-26-094112.md) | [(22.1)](/filings/0001193125-26-344661.md) | [(28.4)](/filings/0001193125-26-344661.md) | [(44.8)](/filings/0001193125-25-277834.md) | [(38.8) d](/filings/0001193125-26-094112.md) | [(42.1)](/filings/0001193125-26-344661.md) | [(56.5)](/filings/0001193125-26-344661.md) |
| Diluted EPS | $ per share | not reported | not reported | [(1562.18)](/filings/0001193125-25-277834.md) | not reported | [(54.23)](/filings/0001193125-26-219829.md) | [(566.46)](/filings/0001193125-26-344661.md) | [(1.03)](/filings/0001193125-25-277834.md) | not reported | [(526.11)](/filings/0001193125-26-219829.md) | [(705.20)](/filings/0001193125-26-344661.md) |
| Basic EPS | $ per share | not reported | not reported | [(1562.18)](/filings/0001193125-25-277834.md) | not reported | [(54.23)](/filings/0001193125-26-219829.md) | [(566.46)](/filings/0001193125-26-344661.md) | [(1.03)](/filings/0001193125-25-277834.md) | not reported | [(526.11)](/filings/0001193125-26-219829.md) | [(705.20)](/filings/0001193125-26-344661.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.0](/filings/0001213900-25-022387.md) | [1.8](/filings/0001213900-24-043582.md) | [1.8](/filings/0001213900-24-068630.md) | [1.8](/filings/0001213900-24-098483.md) | [30.9](/filings/0001193125-26-094112.md) | [1.0](/filings/0001213900-25-044424.md) | [0.7](/filings/0001213900-25-070659.md) | [409](/filings/0001193125-25-277834.md) | [374](/filings/0001193125-26-344661.md) | [52.7](/filings/0001193125-26-219829.md) | [54.1](/filings/0001193125-26-344661.md) |
| Current assets | $m | not reported | not reported | [2.1](/filings/0001213900-24-043582.md) | [2.1](/filings/0001213900-24-068630.md) | [2.0](/filings/0001213900-24-098483.md) | [159](/filings/0001193125-26-094112.md) | [1.2](/filings/0001213900-25-044424.md) | [0.9](/filings/0001213900-25-070659.md) | [476](/filings/0001193125-25-277834.md) | [432](/filings/0001193125-26-344661.md) | [267](/filings/0001193125-26-219829.md) | [242](/filings/0001193125-26-344661.md) |
| Total assets | $m | not reported | [0.3](/filings/0001213900-25-022387.md) | [188](/filings/0001213900-24-043582.md) | [190](/filings/0001213900-24-068630.md) | [192](/filings/0001213900-24-098483.md) | [164](/filings/0001193125-26-094112.md) | [196](/filings/0001213900-25-044424.md) | [197](/filings/0001213900-25-070659.md) | [485](/filings/0001193125-25-277834.md) | [448](/filings/0001193125-26-344661.md) | [418](/filings/0001193125-26-219829.md) | [377](/filings/0001193125-26-344661.md) |
| Current liabilities | $m | not reported | [0.4](/filings/0001213900-25-022387.md) | [0.0](/filings/0001213900-24-043582.md) | [0.1](/filings/0001213900-24-068630.md) | [0.1](/filings/0001213900-24-098483.md) | [19.6](/filings/0001193125-26-094112.md) | [1.9](/filings/0001213900-25-044424.md) | [2.6](/filings/0001213900-25-070659.md) | [35.7](/filings/0001193125-25-277834.md) | [35.0](/filings/0001193125-26-344661.md) | [43.3](/filings/0001193125-26-219829.md) | [51.6](/filings/0001193125-26-344661.md) |
| Total liabilities | $m | not reported | [0.4](/filings/0001213900-25-022387.md) | [5.5](/filings/0001213900-24-043582.md) | [5.6](/filings/0001213900-24-068630.md) | [5.6](/filings/0001213900-24-098483.md) | [19.6](/filings/0001193125-26-094112.md) | [7.4](/filings/0001213900-25-044424.md) | [8.1](/filings/0001213900-25-070659.md) | [38.1](/filings/0001193125-25-277834.md) | [37.3](/filings/0001193125-26-344661.md) | [45.4](/filings/0001193125-26-219829.md) | [53.6](/filings/0001193125-26-344661.md) |
| Shareholders' equity | $m | [(0.0)](/filings/0001213900-24-098483.md) | [(116)](/filings/0001193125-26-094112.md) | [(129)](/filings/0001193125-25-277834.md) | [(143)](/filings/0001193125-25-277834.md) | [(159)](/filings/0001193125-25-277834.md) | [(179)](/filings/0001193125-26-344661.md) | [(200)](/filings/0001193125-26-344661.md) | [(228)](/filings/0001193125-26-344661.md) | [447](/filings/0001193125-25-277834.md) | [411](/filings/0001193125-26-344661.md) | [372](/filings/0001193125-26-344661.md) | [323](/filings/0001193125-26-344661.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.6)](/filings/0001213900-25-044424.md) | [(0.0) d](/filings/0001213900-25-070659.md) | [(39.3) d](/filings/0001193125-25-277834.md) | [(15.0) d](/filings/0001193125-26-094112.md) | [(19.6)](/filings/0001193125-26-219829.md) | [(23.3) d](/filings/0001193125-26-344661.md) | [(28.8) d](/filings/0001193125-25-277834.md) | [(42.2) d](/filings/0001193125-26-094112.md) | [(35.9)](/filings/0001193125-26-219829.md) | [(44.4) d](/filings/0001193125-26-344661.md) |
| Capital expenditure | $m | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-094112.md) | [0.2](/filings/0001193125-26-219829.md) | [0.2 d](/filings/0001193125-26-344661.md) | [0.1 d](/filings/0001193125-25-277834.md) | [0.1 d](/filings/0001193125-26-094112.md) | [0.0](/filings/0001193125-26-219829.md) | [0.0 d](/filings/0001193125-26-344661.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001193125-25-277834.md) | [0.4](/filings/0001193125-26-219829.md) | [50.2](/filings/0001193125-26-344661.md) | [43.5](/filings/0001193125-25-277834.md) | [0.1](/filings/0001193125-26-219829.md) | [80.1](/filings/0001193125-26-344661.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 80,174,267 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344661.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.